title: What is the role of sipuleucel-T in the treatment of patients with advanced prostate cancer? An update on the evidence.
abstract: Prostate cancer is the most common cancer in men and the second most deadly. About one-third of patients with prostate cancer will develop metastatic disease. We discuss the six United States Food and Drug Administration (FDA) approved treatments for metastatic castrate-resistant prostate cancer (mCRPC) with a strong focus on sipuleucel-T. Sipuleucel-T is the first immunotherapy shown to improve survival in asymptomatic or minimally-symptomatic mCRPC. Herein, we discuss the proposed mechanism of sipuleucel-T and its synthesis. We describe in detail the three randomized controlled trials (RTCs) that led to its approval. We also compiled the newest research regarding use of sipuleucel-T with other agents and in different patient populations. Finally, we discuss the current ongoing trials.
authors.affiliation: Department of Medicine, Duke University Medical Center, Durham, NC, USA.
authors.forename: Rachel
authors.initials: R
authors.lastname: Hu
authors.affiliation: Department of Medicine, Duke University Medical Center, Durham, NC, USA.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: George
authors.affiliation: Division of Medical Oncology, Department of Medicine, Duke Cancer Institute, Duke University, DUMC 103861, Durham, NC 27710, USA.
authors.forename: Tian
authors.initials: T
authors.lastname: Zhang
keywords: PROvenge; metastatic castration-resistant prostate cancer; prostate cancer; sipuleucel-T